|4Feb 18, 2:25 PM ET

Cattie Christopher T 4

4 · QNB CORP. · Filed Feb 18, 2026

Research Summary

AI-generated summary of this filing

Updated

QNB CORP (QNBC) COO Christopher T. Cattie Receives Restricted Stock Award

What Happened
Christopher T. Cattie, Chief Operating Officer of QNB CORP (QNBC), received restricted stock awards on February 13, 2026 totaling 1,500 shares. The awards were reported at $38.00 per share: one grant of 750 shares ($28,500) and three derivative-designated grants of 250 shares each (3 × $9,500 = $28,500), for a combined reported value of $57,000. This was an award/grant (A), not an open-market purchase or sale.

Key Details

  • Transaction date: 2026-02-13; Form filed: 2026-02-18 (filed five days after the transaction; exceeds the typical 2-business-day reporting window).
  • Price reported: $38.00 per share.
  • Shares issued: 750 (direct) + 3 × 250 (derivative-designated) = 1,500 total.
  • Total reported value: $57,000.
  • Footnote: F1 — Restricted Stock Award.
  • Shares owned after the transaction: not provided in the excerpt of the filing.

Context
These entries are awards of restricted stock (compensation), which are routinely granted to executives and typically vest over time; they are not immediate open-market purchases (which some investors view as stronger bullish signals). The three entries marked as derivative indicate the awards are derivative-designated restricted shares (e.g., restricted stock units or similar structures that convert to common shares on vesting). Note that the Form 4 was filed five days after the transaction date, which appears later than the usual two-business-day reporting requirement.

Insider Transaction Report

Form 4
Period: 2026-02-13
Cattie Christopher T
EVP Chief Operating Officer
Transactions
  • Award

    Common Stock

    [F1]
    2026-02-13$38.00/sh+750$28,5004,852.017 total
  • Award

    Performance-based restricted stock award

    2026-02-13$38.00/sh+250$9,500250 total
    Exercise: $0.00From: 2026-02-13Exp: 2036-02-13Common Stock (250 underlying)
  • Award

    Performance-based restricted stock award

    2026-02-13$38.00/sh+250$9,500250 total
    Exercise: $0.00From: 2027-02-13Exp: 2036-02-13Common Stock (250 underlying)
  • Award

    Performance-based restricted stock award

    2026-02-13$38.00/sh+250$9,500250 total
    Exercise: $0.00From: 2028-02-13Exp: 2036-02-13Common Stock (250 underlying)
Holdings
  • Common Stock(Right to Buy)

    Exercise: $37.26From: 2025-02-15Exp: 2027-02-15Common Stock (3,500 underlying)
    3,500
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2024-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2025-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2026-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2027-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $29.51From: 2028-02-15Exp: 2033-02-15Common Stock (700 underlying)
    700
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2025-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2026-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2027-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2028-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $23.40From: 2029-02-15Exp: 2034-02-15Common Stock (600 underlying)
    600
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2026-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2027-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2028-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2029-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
  • Common Stock(Right to Buy)

    Exercise: $33.50From: 2030-02-14Exp: 2035-02-14Common Stock (860 underlying)
    860
Footnotes (1)
  • [F1]Restricted Stock Award
Signature
Christopher T Cattie|2026-02-18

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT